These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1748434

  • 1. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
    Pezeshkpour G, Illa I, Dalakas MC.
    Hum Pathol; 1991 Dec; 22(12):1281-8. PubMed ID: 1748434
    [Abstract] [Full Text] [Related]

  • 2. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL.
    N Engl J Med; 1990 Apr 19; 322(16):1098-105. PubMed ID: 2320079
    [Abstract] [Full Text] [Related]

  • 3. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ, McLean KA, Moss J, Woodrow DF.
    Neuropathol Appl Neurobiol; 1993 Oct 19; 19(5):406-13. PubMed ID: 8278024
    [Abstract] [Full Text] [Related]

  • 4. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
    Semino-Mora MC, Leon-Monzon ME, Dalakas MC.
    Lab Invest; 1994 Jul 19; 71(1):102-12. PubMed ID: 7518879
    [Abstract] [Full Text] [Related]

  • 5. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers.
    Gherardi RK, Florea-Strat A, Fromont G, Poron F, Sabourin JC, Authier J.
    Ann Neurol; 1994 Nov 19; 36(5):752-8. PubMed ID: 7979221
    [Abstract] [Full Text] [Related]

  • 6. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy.
    Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA.
    Lancet; 1991 Mar 02; 337(8740):508-10. PubMed ID: 1671889
    [Abstract] [Full Text] [Related]

  • 7. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients.
    Weissman JD, Constantinitis I, Hudgins P, Wallace DC.
    Neurology; 1992 Mar 02; 42(3 Pt 1):619-23. PubMed ID: 1549225
    [Abstract] [Full Text] [Related]

  • 8. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, Roullet E, Gherardi R.
    Ann Neurol; 1991 Jun 02; 29(6):606-14. PubMed ID: 1892364
    [Abstract] [Full Text] [Related]

  • 9. Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA- and nuclear DNA-encoded subunits.
    Yerroum M, Pham-Dang C, Authier FJ, Monnet I, Gherardi R, Chariot P.
    Acta Neuropathol; 2000 Jul 02; 100(1):82-6. PubMed ID: 10912924
    [Abstract] [Full Text] [Related]

  • 10. Prognosis in AZT myopathy.
    Chalmers AC, Greco CM, Miller RG.
    Neurology; 1991 Aug 02; 41(8):1181-4. PubMed ID: 1714057
    [Abstract] [Full Text] [Related]

  • 11. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria.
    Lewis W, Gonzalez B, Chomyn A, Papoian T.
    J Clin Invest; 1992 Apr 02; 89(4):1354-60. PubMed ID: 1556193
    [Abstract] [Full Text] [Related]

  • 12. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.
    Masini A, Scotti C, Calligaro A, Cazzalini O, Stivala LA, Bianchi L, Giovannini F, Ceccarelli D, Muscatello U, Tomasi A, Vannini V.
    J Neurol Sci; 1999 Jul 01; 166(2):131-40. PubMed ID: 10475107
    [Abstract] [Full Text] [Related]

  • 13. HIV or zidovudine myopathy?
    Gherardi R, Chariot P.
    Neurology; 1994 Feb 01; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
    [No Abstract] [Full Text] [Related]

  • 14. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
    Chen SC, Barker SM, Mitchell DH, Stevens SM, O'Neill P, Cunningham AL.
    Pathology; 1992 Apr 01; 24(2):109-11. PubMed ID: 1641255
    [Abstract] [Full Text] [Related]

  • 15. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage.
    Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, Jay CA.
    Ann Neurol; 1994 Apr 01; 35(4):482-7. PubMed ID: 8154877
    [Abstract] [Full Text] [Related]

  • 16. HIV or zidovudine myopathy?
    Dalakas M.
    Neurology; 1994 Feb 01; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract] [Full Text] [Related]

  • 17. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
    Schröder JM, Bertram M, Schnabel R, Pfaff U.
    Acta Neuropathol; 1992 Feb 01; 85(1):39-47. PubMed ID: 1285495
    [Abstract] [Full Text] [Related]

  • 18. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction.
    Semino-Mora MC, Leon-Monzon ME, Dalakas MC.
    Lab Invest; 1994 Nov 01; 71(5):773-81. PubMed ID: 7967528
    [Abstract] [Full Text] [Related]

  • 19. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins.
    de la Asunción JG, del Olmo ML, Sastre J, Millán A, Pellín A, Pallardó FV, Viña J.
    J Clin Invest; 1998 Jul 01; 102(1):4-9. PubMed ID: 9649550
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy.
    Scruggs ER, Dirks Naylor AJ.
    Pharmacology; 2008 Jul 01; 82(2):83-8. PubMed ID: 18504416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.